A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and its Active Metabolite (ACP-5862) when Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Trial Identifier: ACE-HV-114
Sponsor: Acerta Pharma BV
NCTID:: NCT05140096
Start Date: January 2020
Primary Completion Date: April 2020
Study Completion Date: April 2020
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations